

# A CASE OF URINARY INFECTION BY Elizabethkingia meningoseptica

Tiago Danelli\*; Mirella Garcia Saraiva Bueno; Willian Ronqui Belo; Vicente Sanderlei Milani Sabin Medicina Diagnóstica – Londrina – Paraná tiago.danelli@sabin.com.br

### Introduction

*Elizabethkingia meningoseptica* is an increasingly frequent microorganism in healthcare settings. It is especially concerning in patients with previous comorbidities and premature children, presenting high antimicrobial resistance.

# Objective

This work aims to describe a case of urinary tract infection caused by *E. meningoseptica*.



### **Results and Discussion**

An 85-year-old male patient was admitted to the emergency room with a diagnosis of respiratory syndrome and subsequent sepsis of pulmonary origin, but negative for COVID.

Comorbidities: Arterial hypertension, diabetes mellitus, heart disease, dementia, gastrostomy, generalized anxiety disorder, and sequelae from a previous stroke.

He was transferred to the ICU, sedated and intubated. During hospitalization, a urinary infection caused by *E. meningoseptica* resistant to various antimicrobials was diagnosed.

MIC

1,0

8,0

4,0

≥ 64,0

≥ 64,0

≥ 64,0

≥ 64,0

≥ 16,0

≥ 16.0

120

**Resistance\*** 

Susceptible

Intermediate

Intermediate

Resistant

Resistant

Resistant

Resistant

Resistant

Resistant

Resistant

To vancomycin, however, we emphasize that there are no validated breakpoints for this antimicrobial, but rather research that indicates that this may be an option for treatment.

The patient had a bad outcome and after 104 days of hospitalization, passed away.

#### Conclusion

*E. meningoseptica* deserves more attention as it is becoming more frequent in healthcare settings, worsening the prognosis of already weakened patients and being highly resistant to antimicrobials.

Therefore, more studies are necessary to define validated breakpoints with clinical outcomes and to establish an effective therapeutic approach.

MIC: Minimum inhibitory concentration.

Piperacillin/tazobactam ≥ 128,0

Antimicrobial

Ciprofloxacin

Meropenem

Tigecycline

Amikacin

Cefepime

Ceftazidime

Ceftriaxone

Gentamicin

Vancomycin

Imipenem

\*Breakpoints extrapolated from non-enterobacteria; \*\*No validated breakpoints.

# References

JEAN, S.-S. et al. Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia. **Journal of Clinical Medicine**, v. 9, n. 1, p. 275, jan. 2020. JEAN, S. S. et al. Elizabethkingia meningoseptica: an important emerging pathogen causing healthcare-associated infections. **Journal of Hospital Infection**, v. 86, n. 4, p. 244–249, abr. 2014.

LEE, D. H. et al. A Case Series of Elizabethkingia meningosepticum Bacteremia in the Cancer Population. **Cureus**, v. 13, n. 10, p. 11–16, out. 2021. LIN, J.-N. et al. Elizabethkingia Infections in Humans: From Genomics to Clinics. **Microorganisms**, v. 7, n. 9, p. 295, ago. 2019.



Congresso Brasileiro de Patologia Clínica Medicina Laboratorial

32<sup>th</sup> WASPaLM World Congress



Exposição Técnico-Científica | 5 a 8 de setembro | São Paulo, SP - Pro Ma